Canada markets open in 5 hours 5 minutes

Telescope Innovations Corp. (TELIF)

OTC Markets OTCQB - OTC Markets OTCQB Delayed Price. Currency in USD
Add to watchlist
0.3683+0.0685 (+22.85%)
At close: 11:32AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.2998
Open0.3683
Bid0.2700 x 0
Ask0.4000 x 0
Day's Range0.3683 - 0.3683
52 Week Range0.1167 - 0.4107
Volume8,000
Avg. Volume14,641
Market Cap19.765M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Telescope Innovations to Participate in Lithium Supply and Battery Raw Materials Conference 2024

    Vancouver, British Columbia--(Newsfile Corp. - June 11, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, is pleased to announce its participation the 2024 Lithium Supply and Battery Raw Materials Conference hosted by Fastmarkets. The conference will take place on June 24-27 in Las Vegas, NV. Dr. Ryan Jansonius, VP of Chemistry Contract Services fo

  • Newsfile

    Telescope Innovations to Showcase DirectInject-LC(TM) Product and Process IP at METTLER TOLEDO Events

    Vancouver, British Columbia--(Newsfile Corp. - May 13, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, is pleased to announce its participation in two "InfoDays" sponsored by METTLER TOLEDO. Telescope will feature two proprietary innovations during the New Jersey and Montreal InfoDays. InfoDays are high-profile industry and academia networking ev

  • Newsfile

    Telescope Innovations Presents Results of Second Fiscal Quarter 2024

    Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results and operational highlights for the fiscal quarter ended February 29, 2024. The Company generated revenues of $686,205 during this period, driven by strong sales performance of its flagship product, DirectInject-LC™. O